EGFR and non-small cell lung carcinoma: A prospective study of patients with EGFR-mutant stage IIIB/IV NSCLC who were treated with first-line EGFR-TKIs, reported that NLR ≤ 2.90 was associated with better PFS (p = 0.036) and OS (p = 0.026) in multivariate analysis [81].